Median survival extended by 5.7 months! Roche (RHHBY.US) emerges victorious in direct showdown with its new lung cancer drug, providing a major catalyst for its oncology business.
智通财经2026/10/26 03:06Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
According to Zhitong Finance APP, Swiss healthcare and pharmaceutical giant Roche’s investigational lung cancer drug divarasib extended the median survival of patients by nearly six months compared to competing therapies in a late-stage clinical trial, potentially further strengthening the Swiss pharmaceutical company’s oncology treatment portfolio.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Novo founder says AI will spark a gold rush for solo entrepreneurs
智通财经•2026/11/22 02:26


Institutions Warn of U.S. Debt Ceiling Risks, May Provide New Catalyst for Gold
智通财经•2026/11/22 02:06

Tesla launches FSD v15 in the US and rolls out the first batch to EAP members
智通财经•2026/11/22 01:20

Crypto prices
MoreBitcoin
BTC
$60,543.22
+3.03%
Ethereum
ETH
$1,700.92
+2.16%
Tether USDt
USDT
$0.9984
-0.02%
BNB
BNB
$552.01
+3.74%
USDC
USDC
$0.9998
+0.01%
XRP
XRP
$0.9202
+1.45%
Solana
SOL
$70.01
+0.88%
TRON
TRX
$0.3049
+0.70%
Hyperliquid
HYPE
$62.16
+3.94%
Zcash
ZEC
$785.99
+1.68%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now